Abstract
Autophagy is the process by which cellular material is delivered to the lysosome for degradation and recycling. Macroautophagy involves delivery of macromolecules and organelles to double membrane vesicles called autophagosomes that fuse with lysosomes leading to degradation of the contents of the autophagosomes. Chaperone-mediated autophagy involves direct recognition of specific proteins by chaperone complexes that then directly deliver the protein target to the lysosome. Microautophagy involves direct lysosomal capture of cytoplasmic material. Of these three types, macroautophagy is by far the most studied and is known to have multiple roles in cancer development, progression and response to therapy. This has led to autophagy being widely viewed as a potential therapeutic target in cancer. Important questions that must be answered include: Which tumors should or should not be treated by direct autophagy inhibition? And, what is the best way to target autophagy for cancer therapy? In this overview we summarize the background and some current ideas about the answers to such questions.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Amaravadi, R. K., Yu, D., Lum, J. J., Bui, T., Christophorou, M. A., Evan, G. I., et al. (2007). Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. Journal of Clinical Investigation, 117, 326–336.
Arias, E., & Cuervo, A. M. (2011). Chaperone-mediated autophagy in protein quality control. Current Opinion in Cell Biology, 23, 184–189.
Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., Van Moer, K., et al. (2013). Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 110, 17450–17455.
Bago, R., Malik, N., Munson, M. J., Prescott, A. R., Davies, P., Sommer, E., et al. (2014). Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase. The Biochemical Journal, 463, 413–427.
Barnard, R. A., Wittenburg, L. A., Amaravadi, R. K., Gustafson, D. L., Thorburn, A., & Thamm, D. H. (2014). Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy, 10, 1415–1425.
Bursch, W., Ellinger, A., Kienzl, H., Torok, L., Pandey, S., Sikorska, M., et al. (1996). Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: The role of autophagy. Carcinogenesis, 17, 1595–1607.
Chourasia, A. H., Tracy, K., Frankenberger, C., Boland, M. L., Sharifi, M. N., Drake, L. E., et al. (2015). Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. EMBO Reports, 16, 1145–1163.
Dowdle, W. E., Nyfeler, B., Nagel, J., Elling, R. A., Liu, S., Triantafellow, E., et al. (2014). Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nature Cell Biology, 16(11), 1069–1079.
Egan, D. F., Chun, M. G. H., Vamos, M., Zou, H., Rong, J., Miller, C. J., et al. (2015). Small Molecule Inhibition of the autophagy kinase ULK1 and Identification of ULK1 substrates. Molecular Cell, 59, 285–297.
Eng, C. H., Wang, Z., Tkach, D., Toral-Barza, L., Ugwonali, S., Liu, S., et al. (2016). Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proceedings of the National Academy of Sciences of the United States of America, 113, 182–187.
Fitzwalter, B. E., & Thorburn, A. (2015). Recent insights into cell death and autophagy. The FEBS Journal, 282, 4279–4288.
Galluzzi, L., Pietrocola, F., Pedro Bravo-San, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., et al. (2015). Autophagy in malignant transformation and cancer progression. The EMBO Journal, 34(7), 856–880.
Goodall, M. L., Wang, T., Martin, K. R., Kortus, M. G., Kauffman, A. L., Trent, J. M., et al. (2014). Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib. Autophagy, 10, 1120–1136.
Gump, J. M., Staskiewicz, L., Morgan, M. J., Bamberg, A., Riches, D. W. H., & Thorburn, A. (2014). Autophagy variation within a cell population determines cell fate through selective degradation of Fap-1. Nature Cell Biology, 16, 47–54.
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., et al. (2011). Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes and Development, 25, 460–470.
Guo, J. Y., Karsli-Uzunbas, G., Mathew, R., Aisner, S. C., Kamphorst, J. J., Strohecker, A. M., et al. (2013a). Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes and Development, 27, 1447–1461.
Guo, J. Y., Xia, B., & White, E. (2013b). Autophagy-mediated tumor promotion. Cell, 155, 1216–1219.
Hippert, M. M., O’Toole, P. S., & Thorburn, A. (2006). Autophagy in cancer: Good, bad, or both? Cancer Research, 66, 9349–9351.
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13, 714–726.
Huo, Y., Cai, H., Teplova, I., Bowman-Colin, C., Chen, G., Price, S., et al. (2013). Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer. Cancer Discovery, 3, 894–907.
Joshi, S., Tolkunov, D., Aviv, H., Hakimi, A. A., Yao, M., Hsieh, J. J., et al. (2015). The genomic landscape of renal oncocytoma identifies a metabolic barrier to tumorigenesis. Cell Reports, 13, 1895–1908.
Karsli-Uzunbas, G., Guo, J. Y., Price, S., Teng, X., Laddha, S. V., Khor, S., et al. (2014). Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discovery, 4, 914–927.
Kaur, J., & Debnath, J. (2015). Autophagy at the crossroads of catabolism and anabolism. Nature Reviews Molecular Cell Biology, 16, 461–472.
Kaushik, S., Bandyopadhyay, U., Sridhar, S., Kiffin, R., Martinez-Vicente, M., Kon, M., et al. (2011). Chaperone-mediated autophagy at a glance. Journal of Cell Science, 124, 495–499.
Kimmey, J. M., Huynh, J. P., Weiss, L. A., Park, S., Kambal, A., Debnath, J., et al. (2015). Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection. Nature, 528, 565–569.
Kroemer, G. (2015). Autophagy: A druggable process that is deregulated in aging and human disease. Journal of Clinical Investigation, 125, 1–4.
Laddha, S. V., Ganesan, S., Chan, C. S., & White, E. (2014). Mutational landscape of the essential autophagy gene BECN1 in human cancers. Molecular Cancer Research, 12, 485–490.
Lee, I. H., Kawai, Y., Fergusson, M. M., Rovira, I. I., Bishop, A. J. R., Motoyama, N., et al. (2012). Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress. Science, 336, 225–228.
Levy, J. M. M., Thompson, J. C., Griesinger, A. M., Amani, V., Donson, A. M., Birks, D. K., et al. (2014). Autophagy inhibition improves chemosensitivity in BRAFV600E brain tumors. Cancer Discovery, 4, 773–780.
Levy, J. M., & Thorburn, A. (2011). Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacology and Therapeutics, 131, 130–141.
Levy, J. M., & Thorburn, A. (2012). Modulation of pediatric brain tumor autophagy and chemosensitivity. Journal of Neuro-Oncology, 106, 281–290.
Li, Y., Hahn, T., Garrison, K., Cui, Z. H., Thorburn, A., Thorburn, J., et al. (2012). The vitamin E analogue alpha-TEA stimulates tumor autophagy and enhances antigen cross-presentation. Cancer Research, 72, 3535–3545.
Liang, X., de Vera, M. E., Buchser, W. J., Romo De Vivar Chavez, A., Loughran, P., Beer Stolz, D., et al. (2012). Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Research, 72, 2791–2801.
Liang, C., Feng, P., Ku, B., Dotan, I., Canaani, D., Oh, B. H., et al. (2006). Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG. Nature Cell Biology, 8, 688–698.
Lock, R., Kenific, C. M., Leidal, A. M., Salas, E., & Debnath, J. (2014). Autophagy-dependent production of secreted factors facilitates oncogenic RAS-driven invasion. Cancer Discovery, 4, 466–479.
Lock, R., Roy, S., Kenific, C. M., Su, J. S., Salas, E., Ronen, S. M., et al. (2011). Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Molecular Biology of the Cell, 22, 165–178.
Ma, X.-H., Piao, S.-F., Dey, S., McAfee, Q., Karakousis, G., Villanueva, J., et al. (2014). Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. Journal of Clinical Investigation, 124, 1406–1417.
Maejima, I., Takahashi, A., Omori, H., Kimura, T., Takabatake, Y., Saitoh, T., et al. (2013). Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. The EMBO Journal, 32, 2336–2347.
Mancias, J. D., & Kimmelman, A. C. (2011). Targeting autophagy addiction in cancer. Oncotarget, 2, 1302–1306.
Mancias, J. D., Wang, X., Gygi, S. P., Harper, J. W., & Kimmelman, A. C. (2014). Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature, 509, 105–109.
Marino, G., Salvador-Montoliu, N., Fueyo, A., Knecht, E., Mizushima, N., & Lopez-Otin, C. (2007). Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autophagin-3. Journal of Biological Chemistry, 282, 18573–18583.
Martinez-Lopez, N., Athonvarangkul, D., Mishall, P., Sahu, S., & Singh, R. (2013). Autophagy proteins regulate ERK phosphorylation. Nature Communications, 4, 2799.
Maskey, D., Yousefi, S., Schmid, I., Zlobec, I., Perren, A., Friis, R., et al. (2013). ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nature Communications, 4, 2130.
Mathew, R., Khor, S., Hackett, S. R., Rabinowitz, J. D., Perlman, D. H., & White, E. (2014). Functional role of autophagy-mediated proteome remodeling in cell survival signaling and innate immunity. Molecular Cell, 55, 916–930.
Maycotte, P., Aryal, S., Cummings, C. T., Thorburn, J., Morgan, M. J., & Thorburn, A. (2012). Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy, 8, 200–212.
Maycotte, P., Gearheart, C. M., Barnard, R., Aryal, S., Mulcahy Levy, J. M., Fosmire, S. P., et al. (2014). STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Research, 74, 2579–2590.
Maycotte, P., Jones, K. L., Goodall, M. L., Thorburn, J., & Thorburn, A. (2015). Autophagy supports breast cancer stem cell maintenance by regulating IL6 secretion. Molecular Cancer Research, 13(4), 651–658.
Maycotte, P., & Thorburn, A. (2011). Autophagy and cancer therapy. Cancer Biology and Therapy, 11, 127–137.
Mcafee, Q., Zhang, Z., Samanta, A., Levi, S. M., Ma, X.-H., Piao, S., et al. (2012). Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proceedings of the National Academy of Science of the United States of America, 109(21), 8253–8258.
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., et al. (2011). Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science, 334, 1573–1577.
Mizushima, N., Yoshimori, T., & Ohsumi, Y. (2011). The role of Atg proteins in autophagosome formation. Annual Review of Cell and Developmental Biology, 27, 107–132.
Mochida, K., Oikawa, Y., Kimura, Y., Kirisako, H., Hirano, H., Ohsumi, Y., et al. (2015). Receptor-mediated selective autophagy degrades the endoplasmic reticulum and the nucleus. Nature, 522, 359–362.
Morgan, M. J., Gamez, G., Menke, C., Hernandez, A., Thorburn, J., Gidan, F., et al. (2014). Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent. Autophagy, 10, 1814–1826.
Perera, R. M., Stoykova, S., Nicolay, B. N., Ross, K. N., Fitamant, J., Boukhali, M., et al. (2015). Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature, 524, 361–365.
Pérez, E., Das, G., Bergmann, A., & Baehrecke, E. H. (2015). Autophagy regulates tissue overgrowth in a context-dependent manner. Oncogene, 34, 3369–3376.
Petherick, K. J., Conway, O. J. L., Mpamhanga, C., Osborne, S. A., Kamal, A., Saxty, B., et al. (2015). Pharmacological inhibition of ULK1 kinase blocks mammalian target of rapamycin (mTOR)-dependent autophagy. The Journal of Biological Chemistry, 290, 11376–11383.
Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., et al. (2003). Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. Journal of Clinical Investigation, 112, 1809–1820.
Radoshevich, L., Murrow, L., Chen, N., Fernandez, E., Roy, S., Fung, C., et al. (2010). ATG12 conjugation to ATG3 regulates mitochondrial homeostasis and cell death. Cell, 142, 590–600.
Randow, F., & Youle, R. J. (2014). Self and nonself: How autophagy targets mitochondria and bacteria. Cell Host & Microbe, 15, 403–411.
Rangwala, R., Chang, Y. C., Hu, J., Algazy, K., Evans, T., Fecher, L., et al. (2014a). Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy, 10, 1391–1402.
Rangwala, R., Leone, R., Chang, Y. C., Fecher, L., Schuchter, L., Kramer, A., et al. (2014b). Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy, 10, 1369–1379.
Rao, S., Tortola, L., Perlot, T., Wirnsberger, G., Novatchkova, M., Nitsch, R., et al. (2014). A dual role for autophagy in a murine model of lung cancer. Nature Communications, 5, 3056.
Rebecca, V. W., & Amaravadi, R. K. (2015). Emerging strategies to effectively target autophagy in cancer. Oncogene, 35(11), 1–11.
Ronan, B., Flamand, O., Vescovi, L., Dureuil, C., Durand, L., Fassy, F., et al. (2014). A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nature Chemical Biology, 10, 1013–1019.
Rosenfeld, M. R., Ye, X., Supko, J. G., Desideri, S., Grossman, S. A., Brem, S., et al. (2014). A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy, 10, 1359–1368.
Rosenfeldt, M. T., O’Prey, J., Morton, J. P., Nixon, C., MacKay, G., Mrowinska, A., et al. (2013). p53 status determines the role of autophagy in pancreatic tumour development. Nature, 504, 296–300.
Rubinstein, A. D., Eisenstein, M., Ber, Y., Bialik, S., & Kimchi, A. (2011). The autophagy protein Atg12 associates with antiapoptotic Bcl-2 family members to promote mitochondrial apoptosis. Molecular Cell, 44, 698–709.
Rubinsztein, D. C., Codogno, P., & Levine, B. (2012). Autophagy modulation as a potential therapeutic target for diverse diseases. Nature Reviews Drug Discovery, 11, 709–730.
Sahu, R., Kaushik, S., Clement, C. C., Cannizzo, E. S., Scharf, B., Follenzi, A., et al. (2011). Microautophagy of cytosolic proteins by late endosomes. Developmental Cell, 20, 131–139.
Shen, S., Kepp, O., Michaud, M., Martins, I., Minoux, H., Métivier, D., et al. (2011). Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study. Oncogene, 30(45), 4544–4556.
Shimizu, S., Kanaseki, T., Mizushima, N., Mizuta, T., Arakawa-Kobayashi, S., Thompson, C. B., et al. (2004). Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nature Cell Biology, 6, 1221–1228.
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., et al. (2009). Autophagy regulates lipid metabolism. Nature, 458, 1131–1135.
Strohecker, A. M., Guo, J. Y., Karsli-Uzunbas, G., Price, S. M., Chen, G. J., Mathew, R., et al. (2013). Autophagy sustains mitochondrial glutamine metabolism and growth of BRAFV600E-driven lung tumors. Cancer Discovery, 3, 1272–1285.
Subramani, S., & Malhotra, V. (2013). Non-autophagic roles of autophagy-related proteins. EMBO Reports, 14, 143–151.
Takahashi, Y., Coppola, D., Matsushita, N., Cualing, H. D., Sun, M., Sato, Y., et al. (2007). Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nature Cell Biology, 9, 1142–1151.
Takamura, A., Komatsu, M., Hara, T., Sakamoto, A., Kishi, C., Waguri, S., et al. (2011). Autophagy-deficient mice develop multiple liver tumors. Genes and Development, 25, 795–800.
Tang, H., Sebti, S., Titone, R., Zhou, Y., Isidoro, C., Ross, T. S., et al. (2015). Decreased BECN1 mRNA expression in human breast cancer is associated with estrogen receptor-negative subtypes and poor prognosis. EBioMedicine, 2, 255–263.
Thorburn, A. (2008). Studying autophagy’s relationship to cell death. Autophagy, 4, 391–394.
Thorburn, A. (2011). I think autophagy controls the death of my cells: What do I do to get my paper published? Autophagy, 7, 455–456.
Thorburn, A. (2014). Autophagy and its effects: Making sense of double-edged swords. PLoS Biology, 12, e1001967.
Thorburn, J., Horita, H., Redzic, J., Hansen, K., Frankel, A. E., & Thorburn, A. (2009). Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death and Differentiation, 16, 175–183.
Thorburn, A., & Morgan, M. J. (2015). Targeting autophagy in BRAF-mutant tumors. Cancer Discovery, 5, 353–354.
Thorburn, A., Thamm, D. H., & Gustafson, D. L. (2014). Autophagy and cancer therapy. Molecular Pharmacology, 85, 830–838.
Thoresen, S. B., Pedersen, N. M., Liestøl, K., & Stenmark, H. (2010). A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Experimental Cell Research, 316, 3368–3378.
Veldhoen, R. A., Banman, S. L., Hemmerling, D. R., Odsen, R., Simmen, T., Simmonds, A. J., et al. (2013). The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene, 32, 736–746.
Vogl, D. T., Stadtmauer, E. A., Tan, K.-S., Heitjan, D. F., Davis, L. E., Pontiggia, L., et al. (2014). Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy, 10, 1380–1390.
Wei, H., Wang, C., Croce, C. M., & Guan, J.-L. (2014). p62/SQSTM1 synergizes with autophagy for tumor growth in vivo. Genes and Development, 28, 1204–1216.
Wei, H., Wei, S., Gan, B., Peng, X., Zou, W., & Guan, J.-L. (2011). Suppression of autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes and Development, 25, 1510–1527.
Wei, Y., Zou, Z., Becker, N., Anderson, M., Sumpter, R., Xiao, G., et al. (2013). EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell, 154, 1269–1284.
White, E. (2012). Deconvoluting the context-dependent role for autophagy in cancer. Nature Reviews Cancer, 12, 401–410.
Wolpin, B. M., Rubinson, D. A., Wang, X., Chan, J. A., Cleary, J. M., Enzinger, P. C., et al. (2014). Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. The Oncologist, 19, 637–638.
Xie, X., Koh, J. Y., Price, S., White, E., & Mehnert, J. M. (2015). Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discovery, 5, 410–423.
Xie, X., White, E. P., & Mehnert, J. M. (2013). Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One, 8, e55096.
Yang, A., Rajeshkumar, N. V., Wang, X., Yabuuchi, S., Alexander, B. M., Chu, G. C., et al. (2014). Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discovery, 4, 905–913.
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., et al. (2011). Pancreatic cancers require autophagy for tumor growth. Genes and Development, 25, 717–729.
Yue, Z., Jin, S., Yang, C., Levine, A. J., & Heintz, N. (2003). Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proceedings of the National Academy of Sciences of the United States of America, 100, 15077–15082.
Zhao, Z., Oh, S., Li, D., Ni, D., Pirooz, S. D., Lee, J.-H., et al. (2012). A dual role for UVRAG in maintaining chromosomal stability independent of autophagy. Developmental Cell, 22(5), 1001–1016.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Samson, J.M., Thorburn, A. (2016). Autophagy as a Therapeutic Target in Cancer. In: Yang, JM. (eds) Targeting Autophagy in Cancer Therapy. Current Cancer Research. Springer, Cham. https://doi.org/10.1007/978-3-319-42740-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-42740-9_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42738-6
Online ISBN: 978-3-319-42740-9
eBook Packages: MedicineMedicine (R0)